Monkey Pox Testing Market Report 2026

The monkey pox testing market size has grown steadily in recent years. It will grow from $1.52 billion in 2025 to $1.59 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to global spread during 2022 outbreak, limited diagnostic capacity, dependence on centralized laboratories, shortage of test kits, delayed case detection.

The monkey pox testing market size is expected to see steady growth in the next few years. It will grow to $1.88 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to expansion of molecular testing capacity, increasing adoption of point-of-care diagnostics, rising government surveillance initiatives, growth in research funding, development of rapid antigen technologies. Major trends in the forecast period include expansion of advanced molecular diagnostic platforms, adoption of AI-based outbreak prediction and case mapping, growth in iot-enabled remote testing infrastructure, development of high-throughput automated testing systems, increasing integration of cloud-based laboratory data networks.

The increasing incidence of monkeypox disease is expected to drive the growth of the monkeypox testing market in the coming years. Monkeypox is a rare viral infection caused by the monkeypox virus, a member of the Orthopoxvirus genus related to the smallpox virus. The rise in monkeypox cases is attributed to increased human-to-human transmission, global travel, and waning immunity from discontinued smallpox vaccination programs. Monkeypox testing plays a critical role by identifying infected individuals early, enabling timely treatment and isolation to prevent further spread, while also supporting outbreak tracking and understanding transmission patterns. For example, in September 2023, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, 1,131 new confirmed cases of monkeypox were reported between 14 August 2023 and 11 September 2023, along with five related deaths. Therefore, the rising incidence of monkeypox is fueling the growth of the monkeypox testing market.

Leading companies in the monkeypox testing market are focusing on innovative solutions, such as lyophilised RT-PCR kits, to improve diagnostic accessibility and reliability. Lyophilised component technology involves freeze-drying reagents to remain stable at ambient temperatures, eliminating dependence on cold storage and enabling deployment in remote or resource-limited areas without compromising test accuracy. For instance, in August 2024, Andhra Pradesh MedTech Zone (AMTZ), an India-based facility, in partnership with Transasia Diagnostics, launched the ErbaMDx Monkeypox RT-PCR Kit. The kit, validated by the Indian Council for Medical Research (ICMR) and authorized for emergency use by the Central Drugs Standard Control Organisation (CDSCO), features lyophilised reagents, a 12-month shelf life, zero cross-reactivity with other orthopoxviruses, and storage at ambient temperatures. This innovation enhances India’s epidemic preparedness by providing precise, reliable, and accessible monkeypox diagnosis even in areas lacking cold chain infrastructure.

In September 2023, BioNTech, a UK-based biotechnology company, partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) for an undisclosed amount. This collaboration aims to accelerate the development of effective vaccines for monkeypox, a disease that has gained global attention due to recent outbreaks. CEPI is a UK-based public-private organization focused on advancing vaccine development for epidemic preparedness.

Major companies operating in the monkey pox testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Mayo Clinic Laboratories, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Sonic Healthcare Limited, bioMérieux S.A., Bio-Rad Laboratories Inc., QIAGEN N.V., Cepheid Inc., Aegis Sciences Corporation, Chembio Diagnostics Inc., Flow Health Inc., SeraCare Life Sciences Inc., BioGX Inc., Applied DNA Sciences Inc., CerTest Biotec S.L., Altona Diagnostics GmbH, Creative Biogene Inc., ACON Biotech (Hangzhou) Co Ltd.

North America was the largest region in the monkey pox testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monkey pox testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the monkey pox testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on diagnostic reagents, PCR components, and lab equipment have increased manufacturing and import costs for monkeypox testing, especially in countries reliant on external supplies. Laboratory testing and PCR-based diagnostics are the most impacted segments, while regions in Africa, Asia, and South America face higher operational burdens. However, tariffs have encouraged local production of reagents and accelerated investment in domestic diagnostic infrastructure, improving long-term testing resilience.

The monkey pox testing market research report is one of a series of new reports that provides monkey pox testing market statistics, including monkey pox testing industry global market size, regional shares, competitors with a monkey pox testing market share, detailed monkey pox testing market segments, market trends and opportunities, and any further data you may need to thrive in the monkey pox testing industry. This monkey pox testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Monkeypox testing refers to the diagnostic process used to detect the monkeypox virus in individuals. This testing is essential for identifying and confirming cases of monkeypox, a viral zoonotic disease that can be transmitted from animals to humans and between humans.

The main technologies for monkeypox testing include polymerase chain reaction (PCR), lateral flow assay (LFA), and others. PCR is a molecular method used to amplify and detect the DNA of the monkeypox virus in patient samples, serving as a key tool for accurate and early diagnosis. It allows rapid identification of viral genetic material, which is critical for controlling outbreaks. Testing is conducted through laboratory-based methods and point-of-care testing, with end users including hospitals and clinics, diagnostic laboratories, and others.

The monkey pox testing market consist of revenues earned by entities by providing services such as laboratory testing, diagnostic consultation, sample collection, result reporting, contact tracing, and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The monkey pox testing market also includes of sales of serological testing equipment, centrifuges, refrigeration units, biosafety cabinets, automated nucleic acid extractors, and microscopes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.